Fennec Pharmaceuticals (FENC) Non-Current Deffered Revenue (2023 - 2026)

Fennec Pharmaceuticals (FENC) has 3 years of Non-Current Deffered Revenue data on file, last reported at $24.6 million in Q4 2025.

• Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $24.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $24.6 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue steadied at $24.6 million in Q4 2025, from $24.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $25.0 million in Q1 2024 to a low of $2000.0 in Q4 2023.
• A 3-year average of $21.9 million and a median of $24.6 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue surged 1227950.0% — and 2025, when it fell 1.73%.
• Tracing FENC's Non-Current Deffered Revenue over 3 years: stood at $2000.0 in 2023, then surged by 1227950.0% to $24.6 million in 2024, then changed by 0.0% to $24.6 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $24.6 million (Q4 2025), $24.6 million (Q3 2025), and $24.6 million (Q2 2025), per Business Quant data.